Left ventricular volume change and long-term outcomes in ischaemic cardiomyopathy with or without surgical revascularisation: A post-hoc analysis of a randomised controlled trial

Zhuoming Zhou,a,1 Xiaodong Zhuang,b,1 Menghui Liub, Bohao Jian,a Guangguo Fu,a Xinxue Liab, Zhongkai Wu,a and Mengya Liang,a*

aDepartment of Cardiac Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
bDepartment of Cardiology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Summary

Background Whether the association between post-therapeutic left ventricular volume change and long-term outcomes in ischaemic cardiomyopathy is influenced by the performance of coronary artery bypass grafting (CABG) remains unclear. We sought to perform a post-hoc analysis of the Surgical Treatment of Ischaemic Heart Failure (STICH) trial to investigate this association in patients treated with medical therapy (MED) with or without CABG.

Methods From July 24, 2002, to May 5, 2007, 1212 patients with ischaemic cardiomyopathy were enrolled in the STICH trial (NCT00023595) from 99 sites in 22 countries, and were randomly assigned to undergo CABG plus MED or MED alone. We completed a post-hoc analysis of this trial. Patients with paired left ventricular end-systolic volume index (ESVI) measured at baseline and 4-months were included in our analysis. The association between change in ESVI from baseline to 4-months and cardiovascular mortality or all-cause mortality was assessed in MED arm and CABG plus MED arm.

Findings 523 patients were included, with 291 (55.6%) assigned to MED arm and 232 (44.4%) to CABG plus MED arm. At a 4-month follow-up, ESVI reduction was more likely to occur among patients undergoing CABG plus MED. After a median follow-up of 10.3 years, for each 26% (1-standard deviation) decrement in ESVI, it was associated with a 22% lower risk of cardiovascular mortality (HR 0.78; 95% CI, 0.65-0.94) and 19% lower risk of all-cause mortality (HR 0.81; 95% CI, 0.69-0.95) in MED arm, whereas this association was not shown in CABG plus MED arm (cardiovascular mortality: HR 0.90; 95%CI, 0.74-1.10; all-cause mortality: HR 0.93; 95%CI, 0.79-1.09). A 16% reduction in ESVI was determined to be the most appropriate threshold of change in ESVI in the MED arm.

Interpretation In patients with ischaemic cardiomyopathy, left ventricular volume change was associated with long-term prognosis after medical therapy alone, whereas was likely not an optimal benchmark for evaluating the survival benefits associated with CABG. A more than 16% reduction in ESVI might assist in therapeutic efficacy assessment and prognostic evaluation in medically treated patients.

Funding National Natural Science Foundation of China; Natural Science Funds of Guangdong Province.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords: Ischaemic cardiomyopathy; Coronary artery bypass grafting; Left ventricular volume; STICH

Introduction

Ischaemic cardiomyopathy, defined as heart failure with reduced ejection fraction caused by severe coronary artery disease, has resulted in substantial mortality and disability worldwide. Among patients with ischaemic cardiomyopathy, progressive enlargement of left ventricular volume due to infarct expansion, scar formation and decompensated cardiac hypertrophy following...
myocardial infarction, as measured by a higher left ventricular end-systolic volume index (ESVI), has been identified as a strong prognostic predictor.3,4

Left ventricular volume change, which is considered an early signal of pharmacological efficacy on long-term outcomes, can be achieved in patients with ischaemic cardiomyopathy. Our findings have the potential to provide mechanistic insights into how medical therapy or surgical revascularization might affect prognosis, and could be factored into the therapeutic-decision making in clinical practice.

The Surgical Treatment for Ischaemic Heart Failure (STICH) trial was a multicentre randomised controlled trial that investigated the role of CABG plus optimal medical therapy (MED) compared with MED alone in patients with ischaemic cardiomyopathy. By performing a post-hoc analysis of the STICH trial, we sought to (i) investigate the change in ESVI from baseline to 4-month follow-up in patients with ischaemic cardiomyopathy undergoing MED with or without CABG; (ii) study the association between change in ESVI with long-term outcomes and the effect of CABG on this association; and (iii) determine the most appropriate clinical threshold of change in ESVI.

Methods
The present study is a post-hoc analysis of the STICH9 and the STICH extension study (STICHES) (Clinical-Trials.gov registration number NCT00023595). The STICH trial was approved by the institutional review committees at each multicentre and written informed consent was obtained from all participants. The de-identified dataset was obtained from the National Heart, Lung, and Blood Institute’s Biologic Specimen and Data Repository Information Coordinating Centre (BioLINCC) via an approved proposal by the institutional review board of our hospital. Our study complies with the Declaration of Helsinki.

Study population
The study designs and main results of the STICH trial have been published previously. From July 24, 2002, to May 5, 2007, a total of 1212 patients with ischaemic cardiomyopathy [defined as coronary artery disease and left ventricular ejection fraction (LVEF) less than 35%] were enrolled from 99 sites in 22 countries. The inclusion criteria of LVEF less than 35% were determined based on any available imaging assessment performed within 3 months prior to randomisation. For hypothesis 1 of the STICH trial, 1212 patients were included and randomised to optimal medical therapy alone (602 patients) or medical therapy plus CABG (610 patients), and were followed up for a median of 9.8 years.

Among all 1212 patients enrolled in hypothesis 1 of the STICH trial, the following patients were excluded: 1) patients who died within 4-month from the randomisation (n=78); 2) patients without baseline ESVI measured (n=317); 4) patients who did not have paired ESVI measured at 4 months (n=317); 4) patients who did not have paired ESVI measured at baseline and 4-month using the same imaging modality (n=54); 5) patients underwent concomitant surgical ventricular reconstruction (n=6), leaving 523 patients eligible for our study (Supplementary Figure S1).
Imaging data
All 523 included patients have paired imaging data measured at baseline and 4-month follow-up using the same imaging modality. All imaging data were objectively assessed by respective Core Laboratory (Mayo Clinic for echocardiography, University of Southern California for cardiac magnetic resonance, and Northwestern University and Cedars-Sinai Medical Centre for radionuclide) based on standardised methods without knowledge of the patients’ treatment assignment or any clinical data.12,13 The imaging modality was used according to the preferential hierarchy reported by Oh et al.12 We first used the echocardiography data in all patients when available. If the echocardiography data were not available, we then used the cardiac magnetic resonance data, and last to the radionuclide data. Imaging quality was not considered in our imaging priority algorithm. Using this approach, 478 patients with echocardiography data, 11 patients with cardiac magnetic resonance data and 34 patients with radionuclide data were included in our analyses. Left ventricular volume change was represented by percent change in ESVI from baseline to 4-month.

Study outcomes
The study outcomes included cardiovascular mortality and all-cause mortality. The causes of death were adjudicated by an independent blinded committee using pre-specified definitions.

Statistical analysis
All statistical analyses were performed under the intention-to-treat principle. Baseline characteristics of patients in the MED and CABG arms were compared. To evaluate the potential selection bias, we compared the baseline characteristics of the final included and excluded patients (patients who died before the 4-month follow-up were not counted). Continuous variables were presented as the median (25th, 75th, percentiles) or mean (standard deviation) and were compared by Wilcoxon rank-sum test or Student t-test. Categorical data were presented as numbers with percentages and were compared by Pearson’s chi-square or Fisher’s exact tests, if appropriate. Change in ESVI from baseline to 4-month were evaluated by the paired t-test. Sankey diagrams were created using the open access Sankey-MATIC website. The correlation between change in ESVI, change in LVEF, and baseline ESVI was assessed using the Spearman correlation test. The association between change in ESVI and all-cause mortality was assessed by univariable and multivariable cox proportional hazards models, and the proportional hazards assumption was assessed to ensure it was met. Fine and Gray competing risk regression and cumulative incidence functions were used for the risk of cardiovascular mortality, with death from other causes as a competing risk.14 The adjusted covariates were selected based on previously published studies and clinically relevant experience. Different models were examined to investigate the effects of different confounders on the association between change in ESVI and outcomes. Model 1 was adjusted for key demographics including age and sex; Model 2 was adjusted for age, sex, baseline ESVI and baseline LVEF. Model 3 was adjusted for the variables in Model 2 plus baseline comorbidities including diabetes mellitus, atrial fibrillation, renal insufficiency and stroke. The results were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). The visualised relationship between change in ESVI on a continuous scale with HRs of cardiovascular or all-cause mortality was plotted using a multivariable adjusted Cox model with restricted cubic splines. The number of knots was chosen according to the Akaike’s information criterion for best fit: three knots were placed at the default locations (10th, 50th, and 90th percentiles of its distribution). By using the X-tile software (Version 3.6.1, Yale University School of medicine), the most appropriate clinical cut-off value of ESVI reduction was determined according to the highest chi-square value (the lowest log-rank P value) defined by the Kaplan-Meier survival analysis.15 Cumulative event rates were estimated using the Kaplan-Meier method and compared by the log-rank test. Subgroup analyses were performed based on pre-specified clinically accepted thresholds of baseline ESVI (≤ 60 mL/m²; 60–90 mL/m²; and > 90 mL/m²).16 For sensitivity analyses, we then analysed the data based only on 478 patients with paired echocardiographic measurements to test the robustness of our results. We also tested the consistency of our results under the per-protocol principle. All tests were two-sided, and P values less than 0.05 were considered significant. All statistical analyses were performed using R, version 3.6.3 (R Foundation for Statistical Computing, http://www.R-project.org) and STATA, version 14.0 (StataCorp, College Station, TX).

Role of the funding source
The funding source did not have any involvement in study design, data collection, data analysis, data interpretation, the writing of the report, or the decision to submit the paper. All authors confirm that they had full access to all the data in the study and accept the responsibility to submit for publication.

Results
Baseline characteristics of patients
Among the 1212 patients enrolled in hypothesis 1 of the STICH trial, 523 patients with paired ESVI at baseline and 4-month met our inclusion criteria. The baseline
characteristics and clinical outcomes of the 523 included patients were generally similar to the 611 excluded patients, except for diabetes mellitus, hypertension and CABG treatment arm assignment (Supplementary Table S1). Among the 523 included patients, 291 (55.6%) were assigned to the MED arm and 232 (44.4%) to the CABG arm. No significant difference was observed in the baseline characteristics between patients assigned to the MED or CABG arms (Table 1).

**Effect of MED or CABG on left ventricular volume change**

As shown in Figure 1A, ESVI significantly reduced from baseline to 4-month in the CABG arm (85.0 ± 28.6 mL/m² to 81.1 ± 32.9 mL/m², \( P = 0.011 \)), but not in the MED arm (85.0 ± 31.2 mL/m² to 83.8 ± 33.9 mL/m², \( P = 0.301 \)). As shown by the Sankey diagrams delineating the dynamic change of ESVI from baseline to 4-month, the reduction in left ventricular volume is more likely to occur among patients undergoing CABG, compared with medically treated patients (Figure 1B). The distribution of change in ESVI in the MED arm and the CABG arm was shown in Supplementary Figure S2. The change in ESVI for every individual patient was shown in Supplementary Figure S3.

**Left ventricular volume change and outcomes**

After a median follow-up of 10.3 years, 133 cardiovascular mortalities occurred in the MED arm and 86 occurred in the CABG arm. As presented in Figure 2A, restricted cubic splines delineated the patterns of change in ESVI and cardiovascular mortality in all patients, MED arm and CABG arm. The decrement in ESVI was progressively associated with a lower risk of cardiovascular mortality in the overall cohort, and in the MED arm, but not in the CABG arm. For all-cause mortality, 181 occurred in the MED arm and 131 occurred in the CABG arm. Similar patterns between percent change in ESVI and all-cause mortality were presented in Figure 2B.

| Variable                        | Overall (n = 523) | MED (n = 291) | CABG (n = 232) | \( P \) value |
|---------------------------------|------------------|--------------|---------------|--------------|
| Age, years                      | 60.6 ± 9.3       | 60.4 ± 9.5   | 60.7 ± 9.2    | 0.730        |
| Sex, female                     | 63 (12.1)        | 35 (12.0)    | 28 (12.1)     | 0.988        |
| BSA, m²                         | 1.9 ± 0.2        | 1.9 ± 0.2    | 1.9 ± 0.2     | 0.518        |
| NYHA class ≥ grade 3            | 175 (33.5)       | 97 (33.3)    | 78 (33.6)     | 0.945        |
| Diabetes mellitus               | 181 (34.6)       | 101 (34.7)   | 80 (34.5)     | 0.957        |
| Hypertension                    | 292 (55.8)       | 167 (57.4)   | 125 (53.9)    | 0.422        |
| Atrial fibrillation             | 64 (12.2)        | 37 (12.7)    | 27 (11.6)     | 0.709        |
| Renal insufficiency             | 32 (6.1)         | 17 (5.8)     | 15 (6.5)      | 0.758        |
| Stroke                          | 39 (7.5)         | 22 (7.6)     | 17 (7.3)      | 0.920        |
| Baseline LVEF, %                | 28.3 ± 8.4       | 28.5 ± 8.6   | 28.1 ± 8.1    | 0.590        |
| Baseline EDVI, mL/m²            | 116.6 ± 32.4     | 116.7 ± 33.7 | 116.6 ± 30.7  | 0.975        |
| Baseline ESVI, mL/m²            | 85.0 ± 30.0      | 85.0 ± 31.2  | 85.0 ± 28.6   | 0.994        |
| LVEF at 4-month, %              | 29.8 ± 9.9       | 30.0 ± 9.6   | 29.6 ± 10.4   | 0.651        |
| ESVI at 4-month, mL/m²          | 82.6 ± 33.5      | 83.8 ± 33.9  | 81.1 ± 32.9   | 0.368        |
| ESVI < 60 mL/m² at 4-month      | 144 (27.5)       | 77 (26.5)    | 67 (28.9)     | 0.538        |
| Change in LVEF at 4-month, %    | 1.5 ± 9.0        | 1.5 ± 8.6    | 1.5 ± 9.5     | 0.999        |
| Change in ESVI at 4-month, mL/m²| -2.4 ± 21.7      | -1.2 ± 20.3  | -3.9 ± 23.3   | 0.162        |
| Three-vessel disease            | 180 (34.4)       | 101 (34.7)   | 79 (34.1)     | 0.875        |
| Proximal LAD stenosis           | 354 (67.7)       | 198 (68.0)   | 156 (67.2)    | 0.846        |

**Medications at Baseline**

- Beta-blocker: 465 (88.9) MED, 260 (89.4) CABG, 205 (88.4) \( P = 0.722 \)
- Aspirin: 440 (84.1) MED, 250 (85.9) CABG, 190 (81.9) \( P = 0.212 \)
- Statin: 436 (83.4) MED, 243 (83.5) CABG, 193 (83.2) \( P = 0.923 \)
- ACEI/ARB: 475 (90.8) MED, 260 (89.4) CABG, 215 (92.7) \( P = 0.191 \)

**Clinical Outcomes**

- Cardiovascular mortality: 219 (41.9) MED, 133 (45.7) CABG, 86 (37.1) \( P = 0.047 \)
- All-cause mortality: 312 (59.7) MED, 181 (62.2) CABG, 131 (56.5) \( P = 0.184 \)

**Table 1**: Baseline characteristics and clinical outcomes of patients in MED and CABG arm.

Continuous variables were presented as the mean ± standard deviation. Categorical data were presented as numbers (percentages).

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BSA, body surface area; CABG, coronary artery bypass grafting; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; LAD, left anterior descending; LVEF, left ventricular ejection fraction; MED, optimal medical therapy; NYHA, New York Heart Association.
After full adjustment, per 26.0% (1-standard deviation) decrement in ESVI, as a continuous variable, was significantly associated with a 17% lower risk of cardiovascular mortality in the overall cohort (HR 0.83, 95% CI, 0.72-0.95), and a 22% lower risk in MED arm (HR 0.78; 95% CI, 0.65-0.94), but this association was not observed in CABG arm (HR 0.90; 95% CI, 0.74-1.10).

Similarly, per 26.0% (1-standard deviation) decrement in ESVI was significantly associated with a 14% lower risk of all-cause mortality in the overall cohort (HR 0.87; 95% CI, 0.76-0.99).

Figure 1. Change in ESVI from baseline to 4-month follow-up. (A) The overall change in ESVI from baseline to 4-month follow-up in the MED arm and CABG arm. Mean values along with 95% confidence intervals were noted. (B) Sankey diagrams depicting the change in ESVI in MED arm and CABG arm. Compared with medically treated patients, left ventricular volume reduction is more likely to occur among patients undergoing CABG.

*indicates P < 0.05 from a paired t-test.

CABG, coronary artery bypass grafting; ESVI, end-systolic volume index; MED, optimal medical therapy.

Figure 2. Association between change in ESVI and long-term outcomes, delineated by restricted cubic splines. The association between change in ESVI with (A) cardiovascular mortality, and (B) all-cause mortality, in overall patients, MED arm and CABG arm. The reference point is set to a 16% reduction in ESVI. Adjusted for age, sex, baseline ESVI, baseline LVEF, diabetes mellitus, atrial fibrillation, renal insufficiency and stroke.

CABG, coronary artery bypass grafting; ESVI, end-systolic volume index; LVEF, left ventricular ejection fraction; MED, optimal medical therapy.
0.86; 95% CI, 0.77-0.96), and a 19% lower risk in MED arm (HR 0.81; 95% CI, 0.69-0.93), but this association was not observed in CABG arm (HR 0.93; 95% CI, 0.79-1.09) (Table 2). In the sensitivity analyses based on 478 patients with paired echocardiographic measurements, the results remained robust. (Supplementary Table S2). When we excluded patients who crossed over between the MED and the CABG arm, and analysed the remaining 486 patients based on the per-protocol principle, the results remained consistent (Supplementary Table S3). The composite outcome of death from any cause or cardiovascular hospitalisation was analysed as an additional outcome, and the results were summarised in Supplementary Table S4.

**ESVI reduction ≥ 16% and outcomes**

As calculated by the X-tile software, the most appropriate clinical cut-off value of change in ESVI was determined to be a 16% reduction. Of the 523 included patients, 132 (25.2%) had a more than 16% reduction in ESVI, of whom 65 (22.3%) in the MED arm and 67 (28.9%) in the CABG arm. The baseline characteristics of patients with or without a more than 16% reduction in ESVI are summarised in Supplementary Table S5. Patients with a more than 16% reduction in ESVI were more likely to have a history of stroke. After full adjustment, patients with a more than 16% reduction in ESVI were significantly associated with a lower risk of cardiovascular mortality in the overall cohort (HR 0.55; 95% CI, 0.39-0.78), and MED arm (HR 0.62; 95% CI, 0.47-0.81), and MED arm (HR 0.56; 95% CI, 0.38-0.82), but the results was not statistically significant in CABG arm (HR 0.73; 95% CI, 0.49-1.09) (Table 3). Cumulative incidence curves showed that patients with a more than 16% reduction in ESVI had a lower incidence of cardiovascular mortality and all-cause mortality in the overall cohort and MED arm, but no statistical significance was observed in the CABG arm (Figure 3).

**Baseline ESVI, left ventricular volume change and post-therapeutic ESVI**

In both treatment arms, change in ESVI was negatively correlated with baseline ESVI (MED: $r = -0.21$, $P < 0.001$; CABG: $r = -0.16$, $P = 0.017$) (Supplementary Figure S4). Change in LVEF was negatively correlated with change in ESVI (MED: $r = -0.57$, $P < 0.001$; CABG: $r = -0.64$, $P < 0.001$) (Supplementary Figure S5), but was not correlated with baseline ESVI (MED: $r = 0.06$, $P = 0.315$; CABG: $r = 0.06$, $P = 0.142$) (Supplementary Figure S6). The association between a more than 16% reduction in ESVI and clinical outcomes remained generally consistent in the subgroup analyses based on baseline ESVI ($≤$ 60 mL/m$^2$; 60-90 mL/m$^2$; and $> 90$ mL/m$^2$) (Supplementary Table S6). Kaplan-Meier curves showed that patients with post-therapeutic ESVI $< 60$ mL/m$^2$ had a significantly lower incidence of all-cause mortality, both in the MED arm and the CABG arm (Supplementary Figure S7).

**Discussion**

The key findings of the current post-hoc analysis of the STICH trial can be summarised as follows: (i) left ventricular volume reduction was more likely to occur among patients undergoing CABG; (ii) the decreased change in ESVI was associated with a lower risk of cardiovascular and all-cause mortality in patients undergoing medical therapy alone, but this association was not observed in CABG treated patients; (iii) the most

| Outcome                | Group      | No. of Events/ Patients (%) | Change in ESVI from baseline to 4-month, per 1-SD decrement* |
|------------------------|------------|----------------------------|--------------------------------------------------------------|
|                        |            | Unadjusted Model 1 Model 2 Model 3 |
| Cardiovascular Mortality | All patients 219/523 (41.9) 0.93 (0.82-1.05) 0.94 (0.83-1.06) 0.85 (0.74-0.97) 0.83 (0.72-0.95) |
|                        | MED 133/291 (45.7) 0.89 (0.77-1.04) 0.90 (0.77-1.05) 0.80 (0.67-0.95) 0.78 (0.65-0.94) |
|                        | CABG 86/232 (37.1) 1.01 (0.83-1.23) 1.01 (0.84-1.22) 0.93 (0.76-1.13) 0.90 (0.74-1.10) |
| All-cause Mortality    | All patients 312/523 (59.7) 0.96 (0.86-1.06) 0.96 (0.86-1.07) 0.89 (0.79-0.99) 0.86 (0.77-0.96) |
|                        | MED 181/291 (62.2) 0.94 (0.81-1.08) 0.94 (0.81-1.09) 0.83 (0.71-0.97) 0.81 (0.69-0.95) |
|                        | CABG 131/232 (56.5) 1.00 (0.85-1.17) 1.00 (0.86-1.17) 0.96 (0.82-1.13) 0.93 (0.79-1.09) |

Table 2: Association between change in ESVI from baseline to 4-month and long-term outcomes.

CABG, coronary artery bypass grafting; ESVI, end-systolic volume index; LVEF, left ventricular ejection fraction; MED, optimal medical therapy; SD, standard deviation.

Model 1 adjusted for age and sex;
Model 2 adjusted for age, sex, baseline ESVI and baseline LVEF;
Model 3 adjusted for age, sex, baseline ESVI, baseline LVEF, diabetes mellitus, atrial fibrillation, renal insufficiency and stroke.

* Per 1-SD indicates a 26% change in ESVI.
appropriate threshold of change in ESVI on clinical outcomes was determined to be a 16% reduction in ESVI.

In 2019, Panza and his colleagues analysed 318 patients who underwent myocardial viability assessment and had paired imaging in the STICH trial, and found that no association was observed between improvement in LVEF at 4-month follow-up and the subsequent death. Although both LVEF and ESVI were derived from end-systolic volume, these two parameters had different clinical implications: LVEF represents the left ventricular segmental systolic function while ESVI represents the degree of left ventricular size remodeling, and ESVI was generally considered a prognostic indicator independent of LVEF. In the present study, the change in ESVI was analysed as a continuous variable and as a dichotomous variable based on the statistically most appropriate cut-off value, which might provide underlying information associated with left ventricular volume change from different perspectives.

Previous studies have found an association between larger baseline left ventricular volume and poorer clinical outcomes in patients with ischaemic cardiomyopathy. Besides, the therapeutic effects on
left ventricular volume were reported to play beneficial effects on heart failure prognosis after angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs)\(^9,20\) or beta-blockers therapy.\(^7,21,22\) Therefore, in drug development for heart failure, the recovery of left ventricular volume was expected a putative mechanism that mediates the favorable therapeutic effects of medical therapy,\(^7\) and was considered a potential surrogate endpoint on heart failure outcomes.\(^23\) In line with these pioneering investigations, our study supports the relevance of left ventricular volume change as a prognostic factor in pharmacologically treated ischaemic cardiomyopathy patients.

However, the prognostic value of left ventricular volume change was not evident in patients undergoing CABG. Our findings were in accordance with Samady and his colleagues, who reported that failure to improve left ventricular function after surgical revascularisation for ischaemic cardiomyopathy was not associated with worse outcome.\(^24\) Moreover, Michler et al. performed a post-hoc analysis of hypothesis 2 of the STITCH trial and reported that postoperative reduction of ESVI \(\geq 30\%\) was not associated with better prognosis in patients undergoing CABG alone.\(^25\) Taken together with these messages, the left ventricular volume change was likely not associated with the survival benefits of CABG in patients with ischaemic cardiomyopathy.

Our findings showed that change in ESVI from baseline to 4 months was significant in CABG but not MED arm, yet the association between change in ESVI and mortality was significant only in the MED arm. This potential contradiction could be explained from several perspectives. First, the positive therapeutic efficacy of medical therapy on left ventricular remodeling was a long-lasting process and might not completely reveal at an early time point. In some patients with poor medical responsiveness, the recovery of ventricular volume might not occur as early as the 4-month follow-up. Second, patients in the CABG arm also received medical therapy, thus the reduction in ESVI was a concomitant effect of both medical therapy and surgical procedure. Moreover, CABG was more likely to have an immediate or short-term therapeutic efficacy attributed to myocardial revascularisation. For these reasons, it is reasonable that the ESVI reduction in the CABG arm was more significant than the MED arm at 4-month follow-up. Third, the average reduction in ESVI could only represent the overall ESVI change in the entire MED or CABG arm, whereas our findings on the association between change in ESVI and long-term prognosis were derived based on the individual outcome of every independent patient. Our study could provide value in individualised prognostic evaluation, regardless of the average ESVI change in the overall population.

It is noteworthy that the therapeutic mechanism differs between the pharmacological and surgical approaches. The major mechanism of ACEIs/ARBs and beta-blockers in medical therapy is to reduce the left ventricular preload and afterload, decrease oxygen consumption and protect the heart from overwhelming pressure, which plays a crucial role in the attenuation or reversal of left ventricular remodeling.\(^7\) Therefore, change in ESVI could mirror the pharmacological therapeutic efficacy on clinical outcomes. Nevertheless, the main purpose of CABG is to enable complete revascularisation, which increases coronary blood flow to the ischaemic myocardial territories, improves the contractile reserve of the hibernating, and resuscitates stunned myocardium, while ventricular volume appears not to directly measure the intrinsic myocardial recovery.\(^7,26-28\) For these reasons, CABG might have the potential to overcome the detrimental effect of left ventricular enlargement and alleviate the mortality in this population, which might not be accomplished by medical therapy alone. Although our results show that postoperative ESVI \(< 60 \text{ mL/m}^2\) was associated with a lower risk of mortality in CABG patients, the change in ESVI reflects the dynamic process of ventricular size remodeling after CABG, which provides additional information compared with post-operative ESVI at a single time point.

How we should incorporate these findings into the clinical decision needs further elucidation. According to our findings, approximately 25% of ischaemic cardiomyopathy patients had a more than 16% reduction in ESVI at 4-month follow-up, which could be considered as a pragmatic prognostic indicator to evaluate the pharmacological treatment efficacy in patients undergoing medical therapy alone. However, the clinical relevance of the reduction in ESVI was somewhat influenced by the baseline ESVI, as the association between change in ESVI and clinical outcomes became statistically significant only after adjusted for baseline ESVI. For patients undergoing CABG, patients with or without postoperative left ventricular volume recovery nevertheless have similar long-term outcomes. However, we could not rule out the possibility that the lack of statistical significance might be due to the relatively small sample size, whereas the potential association between ESVI reduction and outcomes in the CABG arm could not be completely dismissed. In routine clinical practice, surgeons should not only rely on postoperative left ventricular functional recovery for long-term outcomes evaluation, in order not to underestimate the potential survival benefits achieved by CABG.

Our study should be interpreted within the context of its limitations. First, patients with an increase in ESVI after CABG might potentially have a higher risk of short-term mortality thus were systematically excluded from the study, and the paired ESVI at baseline and 4-month was only available in 523 of the remaining 1134 patients (46.1%). Despite sensitivity analysis proving the robustness of our results, the non-randomised sample might lead to selection bias, and the relatively
limited sample size prevented us from adjusting all potential confounders and might be underpowered for definite conclusions. Second, the therapeutic effect on left ventricular volume change is a time-dependent process thus our interpretation is affected by short-term follow-up ventricular assessment. In addition, the determination of a 16% reduction in ESVI as the clinical threshold was only based on the 4-month endpoint in the current dataset, which should not be considered dogmatic postulates in clinical decisions, and needs external validation before further generalisation. Finally, our findings stemming from 10-year follow-up were based on relatively outdated surgical techniques and medical therapy. However, evidence from contemporary treatments could only be obtained from studies with short-term follow-up. Our findings should be conservatively interpreted and considered only as explorative and hypothesis-generating, but the present study provides a comprehensive depiction into the association between left ventricular volume change, surgical revascularisation and long-term outcomes in patients with ischaemic cardiomyopathy. Besides, these findings have the potential to provide mechanistic insights into how medical therapy or surgical revascularisation might affect prognosis, which helps in clinical therapeutic decision making and could be factored into the design of future investigations.

In conclusion, among patients with ischaemic cardiomyopathy, left ventricular volume change was associated with long-term prognosis after medical therapy alone, whereas was likely not an optimal benchmark for evaluating the survival benefits associated with CABG. A more than 16% reduction in ESVI might assist in therapeutic efficacy evaluation, and could be considered a pragmatic prognostic indicator in medically treated patients.

Contributors
All co-authors have made substantial and intellectual contributions to the work and approved the submitted article. ML and ZW conceived and designed the research, which was then revised and refined by XZ and XL. Data analyses, interpretation and visualisation were performed by ZZ, XZ, ML, BJ and GF. ZZ, ZW and ML have verified the underlying data. The manuscript was written by ZZ and revised by all co-authors. All authors confirm that they had full access to all the data in the study and accept the responsibility to submit for publication.

Data sharing statement
The data are available from the National Heart, Lung, and Blood Institute’s Biologic Specimen and Data Repository Information Coordinating Centre (BioLINCC) via an approved proposal by the institutional review board.

Declaration of interests
The authors declare that there are no conflicts of interest.

Acknowledgements
We thank the investigators of the STICH trial and the staff of the BioLINCC for their contributions. This study was funded by National Natural Science Foundation of China [grant numbers 82070297]; Natural Science Funds of Guangdong Province [grant numbers 2019A1515010218].

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.eclnm.2022.101626.

References
1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–1146.
2. Konstam MA, Kranser DG, Patel AR, Marion MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4(1):98–108.
3. Wrobel K, Stevens SR, Jones RH, et al. Influence of baseline characteristics, operative conduct, and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction: results from the surgical treatment for ischemic heart failure (STICH) trial. Circulation. 2015;132(8):720–730.
4. Pai RG, Varadarajan P, Rouleau JL, et al. Value of cardiovascular magnetic resonance imaging-derived baseline left ventricular ejection fraction and volumes for precise risk stratification of patients with ischemic cardiomyopathy: insights from the surgical treatment for ischemic heart failure (STICH) trial. JAMA Cardiol. 2017;2(3):377–379.
5. Kranser DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2016;68(5):592–406.
6. Reis Filho Jr, Cardoso JN, Cardoso CM, Pereira-Barreto AC. Reverse cardiac remodeling: a marker of better prognosis in heart failure. Arq Bras Cardiol. 2015;104(6):592–596.
7. Jaiswal A, Nguyen VQ, Carry BJ, le Jemtel TH. Pharmacologic and Endovascular Reversal of Left Ventricular Remodeling. J Card Fail. 2016;22(10):829–839.
8. Kottahahi N, Kass DA. Reverse remodeling in heart failure—mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2011;9(3):147–157.
9. Velazquez EJ, Lee KL, Deja MA, et al. coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–1616.
10. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1540–1547.
11. Velazquez EJ, Lee KL, O’Connor CM, et al. The rationale and design of the surgical treatment for ischemic heart failure (STICH) trial. J Thorac Cardiovasc Surg. 2007;134(6):1540–1547.
12. Oh JK, Velazquez EJ, Meniaci I, et al. Influence of baseline left ventricular function on the clinical outcome of surgical ventricular
reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J. 2013;34(1):39–47.
13. Oh JK, Pellikka PA, Panza JA, et al. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012;25(1):327–316.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc. 1999;94(446):496–500.
15. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
16. Bonow RO, Castelvecchio S, Panza JA, et al. Severity of remodeling, myocardial viability, and survival in ischemic LV dysfunction after surgical revascularization. JACC Cardiovasc Imaging. 2015;8(10):1121–1129.
17. Panza JA, Elkin AM, Al-Khalidi HR, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381(8):739–748.
18. Hamer AW, Takayama M, Abraham KA, et al. End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function. Circulation. 1994;90(6):2899–2904.
19. Greenberg B, Quinones MA, Koillipail A, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91(10):2573–2581.
20. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investig Circulat. 1992;86(2):431–438.
21. Calucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REVersive of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation. 2007;116(1):449–56.
22. Gromneg BA, Nilsson JC, Sonderegard I, Fritz-Hansen T, Larsen HB, Hildebrant PR. Anti remodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36(7):2072–2080.
23. Greene SJ, Mentz RJ, Frazier M, et al. Reassessing the role of surrogate end points in drug development for heart failure. Circulation. 2018;138(10):1039–1053.
24. Samady H, Eleftheriades JA, Abbott BG, Mattera JA, McPherson CA, Wackers FJ. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation. 1999;100(12):1298–1304.
25. Michler RE, Rouleau JL, Al-Khalidi HR, et al. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg. 2013;146(5):1139–1145.e6.
26. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation. 1995;91(4):441–444.
27. Lombardo A, Loperfido F, Trani C, et al. Contractile reserve of dysfunctional myocardium after revascularization: a dobutamine stress echocardiography study. J Am Coll Cardiol. 1997;30(4):631–640.
28. Panza JA, Chrzanowski L, Bonow RO. Myocardial viability assessment before surgical revascularization in ischemic cardiomyopathy: JACC review topic of the week. J Am Coll Cardiol. 2021;78(10):1068–1077.